Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial

Trial Profile

Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Plitidepsin (Primary)
  • Indications Liposarcoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms APLIPO
  • Most Recent Events

    • 25 Jul 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 18 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top